Skip to content

MEDITE CANCER DIAGNOSTICS, INC.

CIK 0000075439

← back to feed
Revenue (TTM)
$7.86M
−26.3% YoY Q3 Nov 2018
Net Income (TTM)
−$4.31M
−214.9% YoY Q3 Nov 2018
EPS Diluted (TTM)
—
Q3 Nov 2018
Gross Margin
41.1%
Q3 Nov 2018
Operating Margin
-31.7%
Q3 Nov 2018
Net Margin
-54.8%
Q3 Nov 2018
Free Cash Flow (TTM)
−$2.72M
Q3 Nov 2018
Cash
$147K
Q3 Nov 2018
Total Debt
$5.74M
Q3 Nov 2018
Shares Outstanding
86.72M sh
Q3 Nov 2018

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings